Akèy › Maladi fwa steatotik › Texas › Houston
Etid klinik pou Maladi fwa steatotik nan Houston, TX
13 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- ak 1 plis
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 7 mi lwen
- GSK Investigational Site, Humble · 17 mi lwen
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
- GSK Investigational Site, Bellaire · 7 mi lwen
- GSK Investigational Site, Humble · 17 mi lwen
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
- Pioneer Research Solutions, Inc., Houston
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Ap rekriteFaz 3
- HRI- Medical Center, Houston
- Care Access - Houston, Houston
- Houston Research Institute, Houston
- ak 3 plis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- ak 3 plis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 2
- Houston Research Institute - Medical Center, Houston
- Houston Research Institute, Houston
- Bellaire Clinical Research, Bellaire · 7 mi lwen
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 7 mi lwen
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Ap rekriteFaz 2
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Ap rekriteFaz 1/2Volontè an sante akeyi
- Pioneer Research Solutions, Houston
NAFLD Clinical Care Pathway
Ap rekriteVolontè an sante akeyi
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Ap rekriteEtid obsèvasyon
- First Surgical Hospital, Bellaire · 7 mi lwen
Etid Maladi fwa steatotik nan lòt vil
- San Antonio, TX17 etid
- New York City, NY16 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Richmond, VA12 etid
- Tucson, AZ10 etid
- Chandler, AZ10 etid
- St. Louis, MO9 etid
- Hialeah, FL9 etid
- Dallas, TX9 etid
- Orlando, FL9 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.